Market Overview

UPDATE: Canaccord Genuity Decreases PT on Delcath Systems to $5

Share:
Related DCTH
Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma
Worst Performing Industries For June 2, 2015

According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems (NASDAQ: DCTH) from $8 to $5.

Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).”

Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.

Latest Ratings for DCTH

DateFirmActionFromTo
May 2013WedbushDowngradesOutperformNeutral
May 2013JMP SecuritiesDowngradesMarket OutperformMarket Perform
May 2013Roth CapitalDowngradesBuySell

View More Analyst Ratings for DCTH
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings

 

Related Articles (DCTH)

View Comments and Join the Discussion!

Get Benzinga's Newsletters